💰 AGC, a Japanese pharmaceutical company, is set to build a mammalian cell culture plant with an investment of over $350 million. 🏭 The new plant, located in Chiba, Japan, will produce mammalian cell cultures for biopharmaceutical manufacturing. 🧪 AGC aims to strengthen its position in the biopharmaceutical market by expanding its capabilities in upstream processing. 🌱 The construction of the plant is expected to be completed by 2022.
📢 AGC Invests $350m+ to Build Cutting-Edge Mammalian Plant in Japan
Introduction:
AGC, a Japanese glass and ceramics manufacturer, has announced plans to invest $350 million in building a new mammalian cell culture plant in Japan. The plant will produce active pharmaceutical ingredients (APIs) for biopharmaceuticals, including monoclonal antibodies and other recombinant proteins.
Main points:
- The new plant will be capable of producing APIs for both clinical and commercial use. It will employ AGC’s proprietary “high-grade” cell culture technology, which allows for the production of high-quality proteins.
- The plant will have a total floor area of approximately 9,500 square meters and will be equipped with state-of-the-art facilities and equipment, including bioreactors and purification systems.
- The facility is expected to be completed by the end of 2025 and will have an initial production capacity of several hundred kilograms per year. AGC plans to gradually increase its production capacity to several tons per year.
- AGC aims to capitalize on the growing demand for biopharmaceuticals, especially monoclonal antibodies, which are widely used in the treatment of various diseases, including cancer and autoimmune disorders.
- The new plant will strengthen AGC’s position in the biopharmaceutical market and contribute to the company’s goal of becoming a leading global supplier of APIs for biopharmaceuticals.
Conclusion:
AGC’s investment in building a new mammalian plant highlights the company’s commitment to the biopharmaceutical industry and its ambition to become a major player in the production of APIs for biopharmaceuticals. The new plant will not only meet the increasing demand for biopharmaceuticals but also contribute to the development of innovative therapies for various diseases.
